Researchers use bacteria in new veterinary vaccine design
“We have been working for a long time to deeply understand Mycoplasma pneumoniae and are now ready to take a step forward and use this knowledge for the benefit of society,” Maria Lluch, staff scientist at the Centre for Genomic Regulation (CRG) and scientific co-coordinator of MycoSynVac, said.
This new chassis can help researchers make specific vaccines for two pathogens that are dangerous to livestock animals. These pathogens take large financial losses from the animal industry each year. The new chassis may also be useful for infectious lung disease treatment and for cell therapy.
Researchers have united their biology knowledge with innovative synthetic biology methodologies to make a universal chassis. The goal is a chassis that is optimized for fast growth in a serum-free medium and is also virulence-free.
“We will engineer a new bacteria to be used as a vaccine,” Luis Serrano, CRG director and co-coordinator of this project, said. “We will first remove the genes that make the bacteria pathogenic and then improve the chassis for an optimized growth in a serum-free medium. By expressing specific harmless antigens from one or more pathogens, we can then create targeted vector vaccines.”